What is Sixfold Bioscience?
Sixfold Bioscience operates at the intersection of synthetic biology and pharmaceutical engineering. The company specializes in the development of advanced nucleic acid-based drug delivery systems, specifically engineered to address the delivery challenges inherent in Cell & Gene therapeutics. By focusing on short interfering RNA for gene silencing and messenger RNA for gene expression, Sixfold is tackling some of the most complex hurdles in modern medicine. Their market position is defined by a commitment to precision, utilizing sophisticated delivery architectures to enhance the efficacy and safety profiles of next-generation genetic medicines. As a preclinical-stage entity, the firm maintains a lean, high-impact operational model that prioritizes technical milestones and intellectual property development.
How much funding has Sixfold Bioscience raised?
Sixfold Bioscience has raised a total of $10.5M across 1 funding round:
Angel/Seed
$10.5M
Angel/Seed (2021): $10.5M with participation from Pi Campus, Cantos Ventures, Y Combinator, and Lombardstreet Ventures
Key Investors in Sixfold Bioscience
Pi Campus
Pi Campus is a venture capital firm and startup district based in Rome that focuses on investing in early-stage startups, particularly those applying artificial intelligence to solve significant challenges in traditional industries.
Cantos Ventures
Cantos is focused on investing in near frontier technology that aims to tackle some of the world's largest challenges, supporting technical founders and science-forward enterprises.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and acts as a premier accelerator for high-growth ventures.
What's next for Sixfold Bioscience?
Looking ahead, the infusion of capital will likely be directed toward expanding the company's research capabilities and scaling its delivery platform for broader therapeutic applications. The current funding context suggests a transition toward more intensive preclinical validation, which is essential for attracting future partnerships with major pharmaceutical entities. As the company matures, the focus will shift from foundational research to optimizing delivery efficiency in vivo, a critical step for moving toward clinical trials. Investors are closely monitoring Sixfold's ability to demonstrate consistent, targeted delivery, which remains the primary value driver for the firm's long-term growth trajectory in the biotechnology sector.
See full Sixfold Bioscience company page
